cladribine has been researched along with Adrenocortical Carcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bertele', V; Garattini, S; Gerardi, C; Joppi, R | 1 |
| Csoka, K; de la Torre, M; Fridborg, H; Kristensen, J; Larsson, R; Liliemark, J; Nygren, P | 1 |
1 review(s) available for cladribine and Adrenocortical Carcinoma
| Article | Year |
|---|---|
Letting post-marketing bridge the evidence gap: the case of orphan drugs.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Barrett Esophagus; Cladribine; Dihematoporphyrin Ether; Ductus Arteriosus, Patent; Hepatolenticular Degeneration; Humans; Ibuprofen; Leukemia, Hairy Cell; Mitotane; Orphan Drug Production; Platelet Aggregation Inhibitors; Product Surveillance, Postmarketing; Quinazolines; Thrombocythemia, Essential; Zinc Acetate | 2016 |
1 other study(ies) available for cladribine and Adrenocortical Carcinoma
| Article | Year |
|---|---|
In vitro activity of 2-chlorodeoxyadenosine (CdA) in primary cultures of human haematological and solid tumours.
Topics: Adrenocortical Carcinoma; Breast Neoplasms; Cladribine; Dose-Response Relationship, Drug; Drug Resistance; Drug Screening Assays, Antitumor; Female; Humans; Kidney Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tumor Cells, Cultured | 1994 |